NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00004205,Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer,https://clinicaltrials.gov/study/NCT00004205,BIG 1-98,COMPLETED,"RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen by the tumor cells. If is not yet known which treatment regimen is most effective for breast cancer.

PURPOSE: Randomized double-blind phase III trial to compare the effectiveness of letrozole with that of tamoxifen in treating postmenopausal women who have breast cancer that has been surgically removed.",NO,Breast Cancer,DRUG: letrozole|DRUG: tamoxifen citrate,"Disease free survival., Time from randomization to recurrence (including recurrence restricted to the breast after breast conserving treatment), metastasis, appearance of a second primary tumor, or death from any cause, whichever occurs first, assessed up to end of year 2015, for a maximum of 17 years, Up to end of year 2015","Overall survival, Time from randomization to death from any cause, assessed up to end of year 2015, for a maximum of 17 years, Up to end of year 2015|Safety, Morbidity information will be recorded using the Adverse Event Form (AE)., 5 years after randomization.|Systemic relapse, Time from randomization to appearance of any recurrent or metastatic disease in sites other than the local mastectomy scar, the ipsilateral breast in case of breast conservation, or the contralateral breast, assessed up to end of year 2015, for a maximum of 17 years, Up to end of year 2015",,ETOP IBCSG Partners Foundation,UNICANCER|Danish Breast Cancer Cooperative Group,FEMALE,"ADULT, OLDER_ADULT",PHASE3,8028,NETWORK,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",CDR0000067451|IBCSG-18-98|DAN-DBCG-IBCSG-1-98|FRE-FNCLCC-IBCSG-1-98|EU-99022|NOVARTIS-2026703019|BIG-1-98,1998-03,2008-12,2016-06-30,2003-01-27,,2017-12-12,"Rigshospitalet, Copenhagen, 2100, Denmark|Institut Bergonie, Bordeaux, 33076, France|Kantonsspital - St. Gallen, St. Gallen, CH-9007, Switzerland",
